Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04745026
Status:
COMPLETED
Last Update Posted:
2024-02-20
First Post:
2021-02-04
Brief Title:
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution GWP42003-P CBD-OS in Children and Adolescents With Autism Spectrum Disorder
Sponsor:
Jazz Pharmaceuticals
Organization:
Jazz Pharmaceuticals
Study Overview
Official Title:
An Exploratory Phase 2 Randomized Double-blind Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution GWP42003-P CBD-OS in Children and Adolescents With Autism Spectrum Disorder
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will be conducted to evaluate the efficacy of GWP42003-P compared with placebo in reducing symptom severity in children with Autism Spectrum Disorder ASD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-002819-21 | EUDRACT_NUMBER | None | None |